Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM5VP0F)

• Drug Name: Saphris Drug Info
• Synonyms: Asenapine maleate; Saphris; Asenapine (maleate); Org 5222; Sycrest; Org-5222; Asenapine maleate [USAN]; C17H16ClNO.C4H4O4; Asenapine/; Saphris (TN); EINECS 288-064-8; Org 5222 maleate; trans-5-Chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz(2,3:6,7)oxepino(4,5-c)pyrrole maleate; (S,S)-Asenapine Maleate; SCHEMBL175228; Asenapine maleate (JAN/USAN); CHEBI:71248; GMDCDXMAFMEDAG-CHHFXETESA-N; ABP000604; s1283; MFCD00900588; Asenapine maleate, >=98% (HPLC); AKOS015951084; SCH-900274; MK-8274; CS-0859; HY-11100; AC-24116
• Cross-matching ID:
  PubChem CID: 6917875
  ChEBI ID: CHEBI:71248
  CAS Number: CAS 85650-56-2
  TTD Drug ID: DM5VP0F
  VARIDT Drug ID: DR01717

Molecule-Related Drug Atlas

Drug(s) Transported By P-glycoprotein 1 (ABCB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amoxicillin	DMUYNEI	Acute otitis media	AB00	Approved	[1]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[3]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[4]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[5]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[4]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[4]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[6]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[4]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[7]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[8]

Drug(s) Affected By Cytochrome P450 1A2 (CYP1A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Zolmitriptan	DM1IB4Q	Migraine	8A80	Approved	[9]
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[9]
Etoricoxib	DM6A4NW	Rheumatoid arthritis	FA20	Approved	[9]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[10]
Hesperetin	DMKER83	High blood cholesterol level	5C80.00	Approved	[11]
Stiripentol	DMMSDOY	Dravet syndrome	8A61.11	Approved	[12]
Nifedipine	DMSVOZT	Angina pectoris	BA40	Approved	[13]
Zileuton	DMVRIC2	Allergic asthma	CA23.0	Approved	[14]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[15]
Clonidine	DM6RZ9Q	Attention deficit hyperactivity disorder	6A05.Z	Approved	[16]

Molecular Interaction Atlas of This Drug

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[1]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Cytochrome P450 1A2 (CYP1A2)	OTLLBX48	CP1A2_HUMAN	Gene/Protein Processing	[2]

References

• [1] Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
• [2] Asenapine and iloperidone decrease the expression of major cytochrome P450 enzymes CYP1A2 and CYP3A4 in human hepatocytes. A significance for drug-drug interactions during combined therapy. Toxicol Appl Pharmacol. 2020 Nov 1;406:115239. doi: 10.1016/j.taap.2020.115239. Epub 2020 Sep 14.
• [3] MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
• [4] Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
• [5] Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
• [6] Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
• [7] Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
• [8] Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
• [9] In vitro inhibition of CYP1A2 by model inhibitors, anti-inflammatory analgesics and female sex steroids: predictability of in vivo interactions. Basic Clin Pharmacol Toxicol. 2008 Aug;103(2):157-65.
• [10] Effects of capsaicin and dihydrocapsaicin on human and rat liver microsomal CYP450 enzyme activities in vitro and in vivo. J Asian Nat Prod Res. 2012;14(4):382-95.
• [11] Drug interaction study of flavonoids toward CYP3A4 and their quantitative structure activity relationship (QSAR) analysis for predicting potential effects. Toxicol Lett. 2018 Sep 15;294:27-36.
• [12] Stiripentol. Expert Opin Investig Drugs. 2005 Jul;14(7):905-11.
• [13] Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol. 2000 Feb-Mar;55(11-12):843-52.
• [14] Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. Drug Metab Dispos. 2003 Nov;31(11):1352-60.
• [15] Predictive three-dimensional quantitative structure-activity relationship of cytochrome P450 1A2 inhibitors. J Med Chem. 2005 Jun 2;48(11):3808-15.
• [16] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.